Lukas Biomedical Inc. (TPEX:6814)
Taiwan · Delayed Price · Currency is TWD 28.20
-0.10 (-0.35%)
At close: Feb 11, 2026
Lukas Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -96.22 | -94.38 | -47.35 | -50.07 | -49.49 | -10.54 |
Depreciation & Amortization | 25.99 | 28.52 | 31.57 | 35.96 | 42.73 | 46.9 |
Other Amortization | 0.01 | 0.03 | 0.06 | 0.11 | 0.33 | 1.51 |
Loss (Gain) From Sale of Assets | -0.01 | - | 0.47 | -1.02 | 1.21 | -0.11 |
Loss (Gain) From Sale of Investments | - | - | - | - | - | -0.01 |
Stock-Based Compensation | - | 0.07 | - | - | 0.17 | - |
Provision & Write-off of Bad Debts | 0.22 | 0.2 | -0 | -0.1 | -1.19 | -1.36 |
Other Operating Activities | -0.12 | -0.06 | -0.39 | -0.05 | -0.14 | 0.58 |
Change in Accounts Receivable | -1.52 | 0.8 | 1.41 | 6.27 | 7.26 | 9.64 |
Change in Inventory | -5.37 | -1.3 | 5.68 | -15.51 | -9.24 | -9.79 |
Change in Accounts Payable | -1.46 | -1.25 | -2.03 | 5.8 | 1.18 | 0.78 |
Change in Unearned Revenue | -1.22 | 0.07 | -10.18 | 10.49 | 0.21 | - |
Change in Other Net Operating Assets | 2.42 | -3.24 | 9.02 | 0.69 | -9.19 | -9.07 |
Operating Cash Flow | -77.29 | -70.54 | -11.75 | -7.44 | -16.16 | 29.03 |
Operating Cash Flow Growth | - | - | - | - | - | -50.83% |
Capital Expenditures | -10.7 | -6.81 | -2.66 | -2.98 | -10.03 | -6.64 |
Sale of Property, Plant & Equipment | 0.01 | - | - | - | - | 0.32 |
Sale (Purchase) of Intangibles | - | - | - | - | - | -2.35 |
Investment in Securities | -1.81 | -1.81 | - | - | - | - |
Other Investing Activities | -0.86 | -1.17 | 1 | 5.84 | -0.3 | -2.19 |
Investing Cash Flow | -13.36 | -9.79 | -1.66 | 2.87 | -10.33 | -10.86 |
Short-Term Debt Issued | - | - | 5 | - | 30 | 5 |
Long-Term Debt Issued | - | - | 20 | - | - | - |
Total Debt Issued | -15 | - | 25 | - | 30 | 5 |
Short-Term Debt Repaid | - | -5 | - | -90 | - | - |
Long-Term Debt Repaid | - | -21.65 | -20.29 | -20.34 | -22.38 | -24.05 |
Total Debt Repaid | -28.83 | -26.65 | -20.29 | -110.34 | -22.38 | -24.05 |
Net Debt Issued (Repaid) | -43.83 | -26.65 | 4.71 | -110.34 | 7.62 | -19.05 |
Issuance of Common Stock | - | 140 | - | 90.88 | 45.12 | - |
Other Financing Activities | -0.01 | -0.11 | 0.23 | -0.52 | -0.49 | -0.11 |
Financing Cash Flow | -43.83 | 113.24 | 4.94 | -19.98 | 52.25 | -19.16 |
Net Cash Flow | -134.48 | 32.91 | -8.46 | -24.55 | 25.77 | -0.99 |
Free Cash Flow | -87.99 | -77.35 | -14.41 | -10.41 | -26.18 | 22.39 |
Free Cash Flow Margin | -48.80% | -40.75% | -6.21% | -5.63% | -16.61% | 12.34% |
Free Cash Flow Per Share | -2.10 | -1.95 | -0.39 | -0.28 | -0.80 | 0.68 |
Cash Interest Paid | 2.81 | 2.97 | 2.85 | 2.92 | 4.42 | 4.83 |
Cash Income Tax Paid | 0.04 | 0.03 | 0.01 | - | 0.66 | - |
Levered Free Cash Flow | -51.8 | -41.56 | 3.71 | 8.55 | -8.11 | 23.67 |
Unlevered Free Cash Flow | -50.04 | -39.66 | 5.63 | 10.37 | -5.35 | 26.69 |
Change in Working Capital | -7.15 | -4.92 | 3.9 | 7.74 | -9.78 | -7.92 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.